[Diabetic heart disease].
Kinugawa
Shintaro
S
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine.
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D001713:Biphenyl Compounds; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000378:metabolism / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000150:complications; D003929:Diabetic Neuropathies / Q000150:complications; D006333:Heart Failure / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D007333:Insulin Resistance; D009200:Myocardial Contraction; D009203:Myocardial Infarction / Q000150:complications; D020913:Perindopril / Q000627:therapeutic use; D013777:Tetrazoles / Q000627:therapeutic use; D020257:Ventricular Remodeling
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; C081643:candesartan; D020913:Perindopril